RAF265

• Description:

  RAF265 is a potent and orally active RAF/VEGFR2 inhibitor.

• Product Name Alternative:

  CHIR-265

• UNSPSC:

  12352005

• Hazard Statement:

  H302, H315, H319, H335

• Target:

  Apoptosis; Autophagy; Raf; VEGFR

• Type:

  Reference compound

• Related Pathways:

  Apoptosis; Autophagy; MAPK/ERK Pathway; Protein Tyrosine Kinase/RTK

• Applications:

  Cancer-Kinase/protease

• Field of Research:

  Cancer

• Assay Protocol:

  https://www.medchemexpress.com/RAF265.html

• Purity:

  99.80

• Solubility:

  DMSO : 100 mg/mL (ultrasonic; warming; heat to 60°C) |Ethanol : 10 mg/mL (ultrasonic)

• Smiles:

  FC (F) (C1=CN=C (N1) C2=NC=CC (OC3=CC=C4N (C (NC5=CC=C (C (F) (F) F) C=C5) =NC4=C3) C) =C2) F

• Molecular Formula:

  C24H16F6N6O

• Molecular Weight:

  518.41

• Precautions:

  H302, H315, H319, H335

• References & Citations:

  [1]Mordant P, et al. Dependence on phosphoinositide 3-kinase and RAS-RAF pathways drive the activity of RAF265, a novel RAF/VEGFR2 inhibitor, and RAD001 (Everolimus) in combination. Mol Cancer Ther. 2010 Feb;9 (2) :358-68.

• Shipping Conditions:

  Room Temperature

• Storage Conditions:

  -20°C, 3 years; 4°C, 2 years (Powder)

• Scientific Category:

  Reference compound1

• Clinical Information:

  Phase 2

• Isoform:

  Raf; VEGFR2/KDR/Flk-1

• CAS Number:

  927880-90-8